PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE (PASSIVATE)
Sponsor: AstraZeneca
Terminated
The study was terminated early on 14th September 2023 by the main funding company because of financial futility. We were able to enroll 243 of the initial planned 360 participants and randomised 209 participants of the intial planned 286.
Other terminated trials from AstraZeneca
Other Acute Coronary Syndrome trials with similar outcome
A PHASE2 clinical study on Acute Coronary Syndrome, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Jan 2025 — May 2025 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- National University Heart Centre, Singapore
- University of Otago
For direct contact, visit the study record on ClinicalTrials.gov .